---
document_datetime: 2025-12-02 04:55:45
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/azarga.html
document_name: azarga.html
version: success
processing_time: 0.124848
conversion_datetime: 2025-12-28 13:28:03.633184
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Azarga

[RSS](/en/individual-human-medicine.xml/65461)

##### Authorised

This medicine is authorised for use in the European Union

brinzolamide / timolol Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [Product information - with tracked changes](#product-information-with-tracked-changes-78860)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Azarga. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Azarga.

Expand section

Collapse section

## What is Azarga?

Azarga is a medicine that contains two active substances, brinzolamide and timolol. It is available as eye drops.

## What is Azarga used for?

Azarga is used to reduce intra-ocular pressure (IOP, pressure inside the eye). It is used in adults with open-angle glaucoma (a disease where the pressure in the eye rises because fluid cannot drain out of the eye) or ocular hypertension (when the pressure in the eye is higher than normal). Azarga is used when treatment with a medicine containing only one active substance has been tried but has not reduced the IOP sufficiently.

The medicine can only be obtained with a prescription.

## How is Azarga used?

Azarga is given as one drop into the affected eye(s) twice a day. The suspension needs to be shaken well before use. If it is used with another eye medicine, the different medicines should be used at least 5 minutes apart. If the other eye medicine is an eye ointment it should be used last.

## How does Azarga work?

Raised IOP causes damage to the retina (the light-sensitive surface at the back of the eye) and to the optic nerve that sends signals from the eye to the brain. This can result in serious vision loss and even blindness. By lowering the pressure, Azarga reduces the risk of damage.

Azarga contains two active substances, brinzolamide and timolol. The two substances work by reducing the production of the aqueous humour (the watery fluid in the eye) in different ways. Brinzolamide is a carbonic anhydrase inhibitor that works by blocking an enzyme called carbonic anhydrase, which produces bicarbonate ions in the body. Bicarbonate is required for the production of the aqueous humour. Brinzolamide has been authorised in the European Union (EU) as Azopt since 2000. Timolol is a beta blocker that has been commonly used to treat glaucoma since the 1970s. The combination of the two active substances has an additive effect, reducing the pressure inside the eye more than either medicine alone.

## How has Azarga been studied?

Azarga has been studied in two main studies involving a total of 960 adults with open-angle glaucoma or ocular hypertension. The first was a six-month study comparing Azarga with brinzolamide and with timolol used on their own in 523 patients. The second was a 12-month study comparing Azarga with the combination of timolol and dorzolamide (another carbonic anhydrase inhibitor) in 437 patients. In both studies, the main measure of effectiveness was the change in IOP over the first six months of treatment. IOP was measured in 'millimetres of mercury' (mmHg).

## What benefit has Azarga shown during the studies?

Azarga was more effective than either of the active substances used alone and was as effective as the combination of timolol and dorzolamide. In the first study, IOP fell from around 21 mmHg by 8.0 to 8.7 mmHg in the patients using Azarga. This compared with 5.1 to 5.6 mmHg in those using brinzolamide and 5.7 to 6.9 mmHg in those using timolol. In the second study, IOP had fallen from around 26 mmHg by around 8.3 mmHg after six months in both groups of patients.

## What is the risk associated with Azarga?

The most common side effects with Azarga (seen in between 1 and 10 patients in 100) are blurred vision, eye pain and eye irritation. For the full list of all side effects reported with Azarga, see the package leaflet.

Azarga must not be used in patients who are hypersensitive (allergic) to the active substances, any of the other ingredients, other beta blockers (such as some heart medicines) or sulphonamides (an antibiotic). It must not be used by patients who:

- have or have had asthma;
- have severe chronic obstructive pulmonary disease (COPD, a disease causing narrowing of the airways);
- have certain heart problems;
- have a severe allergic rhinitis (allergy affecting the nose and airways);
- have hyperchloraemic acidosis (excess acid in the blood caused by too much chloride);
- have severely reduced kidney function.

For the full list of restrictions, see the package leaflet.

Azarga contains benzalkonium chloride, which is known to discolour soft contact lenses. Therefore, care should be taken by people who wear soft contact lenses.

## Why has Azarga been approved?

The Committee for Medicinal Products for Human Use (CHMP) noted that combining the two active substances in Azarga simplifies therapy and helps patients to stick to their treatment. The Committee decided that Azarga's benefits are greater than its risks and recommended that it be given marketing authorisation.

## What measures are being taken to ensure the safe and effective use of Azarga?

A risk management plan has been developed to ensure that Azarga is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Azarga, including the appropriate precautions to be followed by healthcare professionals and patients.

## Other information about Azarga

The European Commission granted a marketing authorisation valid throughout the EU for Azarga on 25 November 2008.

For more information about treatment with Azarga, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Azarga : EPAR - Summary for the public

Reference Number: EMA/441131/2013

English (EN) (79.47 KB - PDF)

**First published:** 16/01/2009

**Last updated:** 27/05/2014

[View](/en/documents/overview/azarga-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-42)

български (BG) (130.66 KB - PDF)

**First published:**

16/01/2009

**Last updated:**

27/05/2014

[View](/bg/documents/overview/azarga-epar-summary-public_bg.pdf)

español (ES) (103.2 KB - PDF)

**First published:**

16/01/2009

**Last updated:**

27/05/2014

[View](/es/documents/overview/azarga-epar-summary-public_es.pdf)

čeština (CS) (131.06 KB - PDF)

**First published:**

16/01/2009

**Last updated:**

27/05/2014

[View](/cs/documents/overview/azarga-epar-summary-public_cs.pdf)

dansk (DA) (81.24 KB - PDF)

**First published:**

16/01/2009

**Last updated:**

27/05/2014

[View](/da/documents/overview/azarga-epar-summary-public_da.pdf)

Deutsch (DE) (82.51 KB - PDF)

**First published:**

16/01/2009

**Last updated:**

27/05/2014

[View](/de/documents/overview/azarga-epar-summary-public_de.pdf)

eesti keel (ET) (79.86 KB - PDF)

**First published:**

16/01/2009

**Last updated:**

27/05/2014

[View](/et/documents/overview/azarga-epar-summary-public_et.pdf)

ελληνικά (EL) (132.65 KB - PDF)

**First published:**

16/01/2009

**Last updated:**

27/05/2014

[View](/el/documents/overview/azarga-epar-summary-public_el.pdf)

français (FR) (81.38 KB - PDF)

**First published:**

16/01/2009

**Last updated:**

27/05/2014

[View](/fr/documents/overview/azarga-epar-summary-public_fr.pdf)

hrvatski (HR) (100.21 KB - PDF)

**First published:**

16/01/2009

**Last updated:**

27/05/2014

[View](/hr/documents/overview/azarga-epar-summary-public_hr.pdf)

italiano (IT) (103.01 KB - PDF)

**First published:**

16/01/2009

**Last updated:**

27/05/2014

[View](/it/documents/overview/azarga-epar-summary-public_it.pdf)

latviešu valoda (LV) (103.07 KB - PDF)

**First published:**

16/01/2009

**Last updated:**

27/05/2014

[View](/lv/documents/overview/azarga-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (104.74 KB - PDF)

**First published:**

16/01/2009

**Last updated:**

27/05/2014

[View](/lt/documents/overview/azarga-epar-summary-public_lt.pdf)

magyar (HU) (101.3 KB - PDF)

**First published:**

16/01/2009

**Last updated:**

27/05/2014

[View](/hu/documents/overview/azarga-epar-summary-public_hu.pdf)

Malti (MT) (107.52 KB - PDF)

**First published:**

16/01/2009

**Last updated:**

27/05/2014

[View](/mt/documents/overview/azarga-epar-summary-public_mt.pdf)

Nederlands (NL) (81.65 KB - PDF)

**First published:**

16/01/2009

**Last updated:**

27/05/2014

[View](/nl/documents/overview/azarga-epar-summary-public_nl.pdf)

polski (PL) (107.7 KB - PDF)

**First published:**

16/01/2009

**Last updated:**

27/05/2014

[View](/pl/documents/overview/azarga-epar-summary-public_pl.pdf)

português (PT) (80.4 KB - PDF)

**First published:**

16/01/2009

**Last updated:**

27/05/2014

[View](/pt/documents/overview/azarga-epar-summary-public_pt.pdf)

română (RO) (102.14 KB - PDF)

**First published:**

16/01/2009

**Last updated:**

27/05/2014

[View](/ro/documents/overview/azarga-epar-summary-public_ro.pdf)

slovenčina (SK) (128.11 KB - PDF)

**First published:**

16/01/2009

**Last updated:**

27/05/2014

[View](/sk/documents/overview/azarga-epar-summary-public_sk.pdf)

slovenščina (SL) (123.08 KB - PDF)

**First published:**

16/01/2009

**Last updated:**

27/05/2014

[View](/sl/documents/overview/azarga-epar-summary-public_sl.pdf)

Suomi (FI) (80.09 KB - PDF)

**First published:**

16/01/2009

**Last updated:**

27/05/2014

[View](/fi/documents/overview/azarga-epar-summary-public_fi.pdf)

svenska (SV) (79.76 KB - PDF)

**First published:**

16/01/2009

**Last updated:**

27/05/2014

[View](/sv/documents/overview/azarga-epar-summary-public_sv.pdf)

Azarga : EPAR - Risk management plan summary

English (EN) (49.57 KB - PDF)

**First published:** 17/11/2021

[View](/en/documents/rmp-summary/azarga-epar-risk-management-plan-summary_en.pdf)

## Product information

Azarga : EPAR - Product Information

English (EN) (387.51 KB - PDF)

**First published:** 08/01/2009

**Last updated:** 02/09/2025

[View](/en/documents/product-information/azarga-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-889)

български (BG) (467.71 KB - PDF)

**First published:**

08/01/2009

**Last updated:**

02/09/2025

[View](/bg/documents/product-information/azarga-epar-product-information_bg.pdf)

español (ES) (370.13 KB - PDF)

**First published:**

08/01/2009

**Last updated:**

02/09/2025

[View](/es/documents/product-information/azarga-epar-product-information_es.pdf)

čeština (CS) (380.95 KB - PDF)

**First published:**

08/01/2009

**Last updated:**

02/09/2025

[View](/cs/documents/product-information/azarga-epar-product-information_cs.pdf)

dansk (DA) (387.21 KB - PDF)

**First published:**

08/01/2009

**Last updated:**

02/09/2025

[View](/da/documents/product-information/azarga-epar-product-information_da.pdf)

Deutsch (DE) (407.33 KB - PDF)

**First published:**

08/01/2009

**Last updated:**

02/09/2025

[View](/de/documents/product-information/azarga-epar-product-information_de.pdf)

eesti keel (ET) (352.83 KB - PDF)

**First published:**

08/01/2009

**Last updated:**

02/09/2025

[View](/et/documents/product-information/azarga-epar-product-information_et.pdf)

ελληνικά (EL) (436.86 KB - PDF)

**First published:**

08/01/2009

**Last updated:**

02/09/2025

[View](/el/documents/product-information/azarga-epar-product-information_el.pdf)

français (FR) (376.49 KB - PDF)

**First published:**

08/01/2009

**Last updated:**

02/09/2025

[View](/fr/documents/product-information/azarga-epar-product-information_fr.pdf)

hrvatski (HR) (420.05 KB - PDF)

**First published:**

08/01/2009

**Last updated:**

02/09/2025

[View](/hr/documents/product-information/azarga-epar-product-information_hr.pdf)

íslenska (IS) (354.71 KB - PDF)

**First published:**

08/01/2009

**Last updated:**

02/09/2025

[View](/is/documents/product-information/azarga-epar-product-information_is.pdf)

italiano (IT) (403.33 KB - PDF)

**First published:**

08/01/2009

**Last updated:**

02/09/2025

[View](/it/documents/product-information/azarga-epar-product-information_it.pdf)

latviešu valoda (LV) (414.88 KB - PDF)

**First published:**

08/01/2009

**Last updated:**

02/09/2025

[View](/lv/documents/product-information/azarga-epar-product-information_lv.pdf)

lietuvių kalba (LT) (406.37 KB - PDF)

**First published:**

08/01/2009

**Last updated:**

02/09/2025

[View](/lt/documents/product-information/azarga-epar-product-information_lt.pdf)

magyar (HU) (439.79 KB - PDF)

**First published:**

08/01/2009

**Last updated:**

02/09/2025

[View](/hu/documents/product-information/azarga-epar-product-information_hu.pdf)

Malti (MT) (537.1 KB - PDF)

**First published:**

08/01/2009

**Last updated:**

02/09/2025

[View](/mt/documents/product-information/azarga-epar-product-information_mt.pdf)

Nederlands (NL) (358.93 KB - PDF)

**First published:**

08/01/2009

**Last updated:**

02/09/2025

[View](/nl/documents/product-information/azarga-epar-product-information_nl.pdf)

norsk (NO) (369.85 KB - PDF)

**First published:**

08/01/2009

**Last updated:**

02/09/2025

[View](/no/documents/product-information/azarga-epar-product-information_no.pdf)

polski (PL) (478.54 KB - PDF)

**First published:**

08/01/2009

**Last updated:**

02/09/2025

[View](/pl/documents/product-information/azarga-epar-product-information_pl.pdf)

português (PT) (409.65 KB - PDF)

**First published:**

08/01/2009

**Last updated:**

02/09/2025

[View](/pt/documents/product-information/azarga-epar-product-information_pt.pdf)

română (RO) (419.22 KB - PDF)

**First published:**

08/01/2009

**Last updated:**

02/09/2025

[View](/ro/documents/product-information/azarga-epar-product-information_ro.pdf)

slovenčina (SK) (454.69 KB - PDF)

**First published:**

08/01/2009

**Last updated:**

02/09/2025

[View](/sk/documents/product-information/azarga-epar-product-information_sk.pdf)

slovenščina (SL) (446.26 KB - PDF)

**First published:**

08/01/2009

**Last updated:**

02/09/2025

[View](/sl/documents/product-information/azarga-epar-product-information_sl.pdf)

Suomi (FI) (373.19 KB - PDF)

**First published:**

08/01/2009

**Last updated:**

02/09/2025

[View](/fi/documents/product-information/azarga-epar-product-information_fi.pdf)

svenska (SV) (382.68 KB - PDF)

**First published:**

08/01/2009

**Last updated:**

02/09/2025

[View](/sv/documents/product-information/azarga-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000294072 01/09/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Azarga : EPAR - All Authorised presentations

English (EN) (7.08 KB - PDF)

**First published:** 08/01/2009

**Last updated:** 08/01/2009

[View](/en/documents/all-authorised-presentations/azarga-epar-all-authorised-presentations_en.pdf)

[Other languages (21)](#file-language-dropdown-431)

български (BG) (70.44 KB - PDF)

**First published:**

08/01/2009

**Last updated:**

08/01/2009

[View](/bg/documents/all-authorised-presentations/azarga-epar-all-authorised-presentations_bg.pdf)

español (ES) (7.42 KB - PDF)

**First published:**

08/01/2009

**Last updated:**

08/01/2009

[View](/es/documents/all-authorised-presentations/azarga-epar-all-authorised-presentations_es.pdf)

čeština (CS) (75.11 KB - PDF)

**First published:**

08/01/2009

**Last updated:**

08/01/2009

[View](/cs/documents/all-authorised-presentations/azarga-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (7.49 KB - PDF)

**First published:**

08/01/2009

**Last updated:**

08/01/2009

[View](/da/documents/all-authorised-presentations/azarga-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (7.22 KB - PDF)

**First published:**

08/01/2009

**Last updated:**

08/01/2009

[View](/de/documents/all-authorised-presentations/azarga-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (7.28 KB - PDF)

**First published:**

08/01/2009

**Last updated:**

08/01/2009

[View](/et/documents/all-authorised-presentations/azarga-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (67.23 KB - PDF)

**First published:**

08/01/2009

**Last updated:**

08/01/2009

[View](/el/documents/all-authorised-presentations/azarga-epar-all-authorised-presentations_el.pdf)

français (FR) (7.57 KB - PDF)

**First published:**

08/01/2009

**Last updated:**

08/01/2009

[View](/fr/documents/all-authorised-presentations/azarga-epar-all-authorised-presentations_fr.pdf)

italiano (IT) (7.43 KB - PDF)

**First published:**

08/01/2009

**Last updated:**

08/01/2009

[View](/it/documents/all-authorised-presentations/azarga-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (69.88 KB - PDF)

**First published:**

08/01/2009

**Last updated:**

08/01/2009

[View](/lv/documents/all-authorised-presentations/azarga-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (70.74 KB - PDF)

**First published:**

08/01/2009

**Last updated:**

08/01/2009

[View](/lt/documents/all-authorised-presentations/azarga-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (36.85 KB - PDF)

**First published:**

08/01/2009

**Last updated:**

08/01/2009

[View](/hu/documents/all-authorised-presentations/azarga-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (75.74 KB - PDF)

**First published:**

08/01/2009

**Last updated:**

08/01/2009

[View](/mt/documents/all-authorised-presentations/azarga-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (7 KB - PDF)

**First published:**

08/01/2009

**Last updated:**

08/01/2009

[View](/nl/documents/all-authorised-presentations/azarga-epar-all-authorised-presentations_nl.pdf)

polski (PL) (38.47 KB - PDF)

**First published:**

08/01/2009

**Last updated:**

08/01/2009

[View](/pl/documents/all-authorised-presentations/azarga-epar-all-authorised-presentations_pl.pdf)

português (PT) (7.53 KB - PDF)

**First published:**

08/01/2009

**Last updated:**

08/01/2009

[View](/pt/documents/all-authorised-presentations/azarga-epar-all-authorised-presentations_pt.pdf)

română (RO) (69.65 KB - PDF)

**First published:**

08/01/2009

**Last updated:**

08/01/2009

[View](/ro/documents/all-authorised-presentations/azarga-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (73.21 KB - PDF)

**First published:**

08/01/2009

**Last updated:**

08/01/2009

[View](/sk/documents/all-authorised-presentations/azarga-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (42.14 KB - PDF)

**First published:**

08/01/2009

**Last updated:**

08/01/2009

[View](/sl/documents/all-authorised-presentations/azarga-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (7.44 KB - PDF)

**First published:**

08/01/2009

**Last updated:**

08/01/2009

[View](/fi/documents/all-authorised-presentations/azarga-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (7.49 KB - PDF)

**First published:**

08/01/2009

**Last updated:**

08/01/2009

[View](/sv/documents/all-authorised-presentations/azarga-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Azarga Active substance

- brinzolamide
- timolol maleate

International non-proprietary name (INN) or common name

- brinzolamide
- timolol

Therapeutic area (MeSH)

- Glaucoma, Open-Angle
- Ocular Hypertension

Anatomical therapeutic chemical (ATC) code S01ED51

### Pharmacotherapeutic group

Ophthalmologicals

### Therapeutic indication

Decrease of intraocular pressure (IOP) in adult patients with open angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction.

## Authorisation details

EMA product number EMEA/H/C/000960 Marketing authorisation holder

Novartis Europharm Limited

Vista Building

Marketing authorisation issued 25/11/2008 Revision 18

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Azarga : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (148.88 KB - PDF)

**First published:** 02/09/2025

[View](/en/documents/procedural-steps-after/azarga-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Azarga : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (184.1 KB - PDF)

**First published:** 13/01/2010

**Last updated:** 02/09/2025

[View](/en/documents/procedural-steps-after/azarga-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Azarga : EPAR - Public assessment report

English (EN) (1.97 MB - PDF)

**First published:** 08/01/2009

**Last updated:** 08/01/2009

[View](/en/documents/assessment-report/azarga-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Azarga

Reference Number: EMEA/CHMP/472224/2008

English (EN) (76.02 KB - PDF)

**First published:** 25/09/2008

**Last updated:** 25/09/2008

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-azarga_en.pdf)

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Azarga : EPAR - Product information - tracked changes

English (EN) (115.05 KB - DOCX)

**First published:** 02/09/2025

[View](/en/documents/product-information-tracked-changes/azarga-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-782)

български (BG) (133.25 KB - DOCX)

**First published:**

02/09/2025

[View](/bg/documents/product-information-tracked-changes/azarga-epar-product-information-tracked-changes_bg.docx)

español (ES) (117.37 KB - DOCX)

**First published:**

02/09/2025

[View](/es/documents/product-information-tracked-changes/azarga-epar-product-information-tracked-changes_es.docx)

čeština (CS) (97.87 KB - DOCX)

**First published:**

02/09/2025

[View](/cs/documents/product-information-tracked-changes/azarga-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (110.58 KB - DOCX)

**First published:**

02/09/2025

[View](/da/documents/product-information-tracked-changes/azarga-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (125.23 KB - DOCX)

**First published:**

02/09/2025

[View](/de/documents/product-information-tracked-changes/azarga-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (111.87 KB - DOCX)

**First published:**

02/09/2025

[View](/et/documents/product-information-tracked-changes/azarga-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (138.45 KB - DOCX)

**First published:**

02/09/2025

[View](/el/documents/product-information-tracked-changes/azarga-epar-product-information-tracked-changes_el.docx)

français (FR) (114.05 KB - DOCX)

**First published:**

02/09/2025

[View](/fr/documents/product-information-tracked-changes/azarga-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (124.4 KB - DOCX)

**First published:**

02/09/2025

[View](/hr/documents/product-information-tracked-changes/azarga-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (110.84 KB - DOCX)

**First published:**

02/09/2025

[View](/is/documents/product-information-tracked-changes/azarga-epar-product-information-tracked-changes_is.docx)

italiano (IT) (111.83 KB - DOCX)

**First published:**

02/09/2025

[View](/it/documents/product-information-tracked-changes/azarga-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (104.22 KB - DOCX)

**First published:**

02/09/2025

[View](/lv/documents/product-information-tracked-changes/azarga-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (93.83 KB - DOCX)

**First published:**

02/09/2025

[View](/lt/documents/product-information-tracked-changes/azarga-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (116.34 KB - DOCX)

**First published:**

02/09/2025

[View](/hu/documents/product-information-tracked-changes/azarga-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (104.84 KB - DOCX)

**First published:**

02/09/2025

[View](/mt/documents/product-information-tracked-changes/azarga-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (123.69 KB - DOCX)

**First published:**

02/09/2025

[View](/nl/documents/product-information-tracked-changes/azarga-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (111.57 KB - DOCX)

**First published:**

02/09/2025

[View](/no/documents/product-information-tracked-changes/azarga-epar-product-information-tracked-changes_no.docx)

polski (PL) (103.75 KB - DOCX)

**First published:**

02/09/2025

[View](/pl/documents/product-information-tracked-changes/azarga-epar-product-information-tracked-changes_pl.docx)

português (PT) (104.65 KB - DOCX)

**First published:**

02/09/2025

[View](/pt/documents/product-information-tracked-changes/azarga-epar-product-information-tracked-changes_pt.docx)

română (RO) (98.66 KB - DOCX)

**First published:**

02/09/2025

[View](/ro/documents/product-information-tracked-changes/azarga-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (131.89 KB - DOCX)

**First published:**

02/09/2025

[View](/sk/documents/product-information-tracked-changes/azarga-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (115.18 KB - DOCX)

**First published:**

02/09/2025

[View](/sl/documents/product-information-tracked-changes/azarga-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (115.32 KB - DOCX)

**First published:**

02/09/2025

[View](/fi/documents/product-information-tracked-changes/azarga-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (100.53 KB - DOCX)

**First published:**

02/09/2025

[View](/sv/documents/product-information-tracked-changes/azarga-epar-product-information-tracked-changes_sv.docx)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 02/09/2025

## Share this page

[Back to top](#main-content)